Las Vegas—The investigational monoclonal antibody (MAB) galcanezumab has demonstrated efficacy in preventing both episodic and chronic migraine in new phase 3 clinical trials.
FEBRUARY 15, 2018
New Monoclonal Antibody Targets Pathway to Prevent Migraine